{
    "eid": "2-s2.0-85088610614",
    "title": "Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?",
    "cover-date": "2020-08-15",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "HBsAg seroloss",
        "HBV",
        "HIV",
        "long-term ART",
        "tenofovir"
    ],
    "authors": [
        "Jennifer Audsley",
        "Anchalee Avihingsanon",
        "Margaret Littlejohn",
        "Scott Bowden",
        "Gail V. Matthews",
        "Christopher K. Fairley",
        "Sharon R. Lewin",
        "Joe Sasadeusz"
    ],
    "citedby-count": 12,
    "ref-count": 42,
    "ref-list": [
        "HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy",
        "HIV/AIDS in Asia",
        "Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013",
        "BHIVA Guidelines: Coinfection with HIV and Chronic hepatitis B virus",
        "Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men",
        "HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)",
        "HIV-hepatitis B virus coinfection: Epidemiology, pathogenesis, and treatment",
        "Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations",
        "Long-Term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus",
        "Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus",
        "Patterns and causes of suboptimal response to tenofovir based therapy in HIV-HBV infected individuals",
        "Hepatitis B virus infection",
        "HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: Clinical outcomes and durability",
        "Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy",
        "HIV-HBV coinfection in Southern Africa and the effect of lamivudine-versus tenofovir-containing cART on HBV outcomes",
        "Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals",
        "Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-na\u00efve patients with chronic hepatitis B",
        "Effects of long-Term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity",
        "In Vitro studies show that sequence variability contributes to marked variation in hepatitis B virus replication, protein expression, and function observed across genotypes",
        "Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate",
        "Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-Term follow-up of patients coinfected with HIV and hepatitis B virus",
        "Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa",
        "Outcomes in HIV/HBV-coinfected patients in the tenofovir era are greatly affected by immune suppression",
        "Hepatitis B surface antigen concentrations in patients with HIV/HBV Co-infection",
        "Five-year on-Treatment efficacy of lamivudine-, tenofovir-And tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients",
        "Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients",
        "Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: Relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion",
        "Hepatitis B surface antigen declines and clearance during long-Term tenofovir therapy in patients coinfected with HBV and HIV",
        "CD4+ cell count 6 Years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression",
        "Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion",
        "Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection",
        "Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients",
        "HIV-specific CD8 T cells producing CCL-4 are associated with worse immune reconstitution during chronic infection",
        "Central memory CD4 cells are an early indicator of immune reconstitution in HIV/AIDS patients with anti-retroviral treatment",
        "Low double-negative CD3(+)CD4(-)CD8(-) T cells are associated with incomplete restoration of CD4(+) T cells and higher immune activation in HIV-1 immunological non-responders",
        "Care of patients with chronic hepatitis B and HIV co-infection: Recommendations from an HIV-HBV international panel",
        "Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals",
        "Use of hepatitis B surface and \"e\" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV",
        "Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort",
        "Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-Term nucleos(t)ide analogues",
        "Interactions between HIV and hepatitis B virus in homosexual men: Effects on the natural history of infection"
    ],
    "affiliation": [
        {
            "affiliation-city": "Melbourne",
            "@id": "60005245",
            "affilname": "Royal Melbourne Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005245",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Kensington",
            "@id": "60026655",
            "affilname": "The Kirby Institute",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026655",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Melbourne",
            "@id": "60026553",
            "affilname": "University of Melbourne",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026553",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Sydney",
            "@id": "60025702",
            "affilname": "St. Vincent's Hospital Sydney",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025702",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Melbourne",
            "@id": "60023619",
            "affilname": "Melbourne Sexual Health Centre",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60023619",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Melbourne",
            "@id": "60019578",
            "affilname": "Monash University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60019578",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Clayton",
            "@id": "60012932",
            "affilname": "Faculty of Medicine, Nursing and Health Sciences",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012932",
            "affiliation-country": "Australia"
        }
    ],
    "funding": [
        "American Foundation for AIDS Research",
        "National Health and Medical Research Council of Australia",
        "National Institutes of Health",
        "amfAR",
        "Merck",
        "Gilead Sciences",
        "NHMRC"
    ]
}